Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

f the other Janssen Pharmaceutical Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; impact of business combinations; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

Media Contact: Daniel De Schryver               
Mobile: +49 173 76 89 149

Media Contact: Craig Stoltz               
Mobile: +1 (215) 325-3612

Investor Contact: Stan Panasewicz                      
Off
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, ... Touch® , an innovative vaginal health laser procedure that prevents and resolves dryness ... for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... real-time monitoring and analysis of pet vital signs and activity, today announced its ... one of the most popular and widely-adopted veterinary hospital Practice Management Software packages ...
(Date:9/1/2015)... ME (PRWEB) , ... September 01, 2015 , ... Royal ... large, new study that followed men and women for 19 years and found that, ... who did not take multivitamins. , The report is part of the September 2015 ...
(Date:9/1/2015)... D.C. (PRWEB) , ... September 01, 2015 , ... Two ... better cross cultural relations through food and dining. , Recently named “the next ... and Luigi Diotaiuti are known for telling the whole story behind food and reclaiming ...
(Date:9/1/2015)... ... September 01, 2015 , ... METTLER TOLEDO ... available. With the Connectivity Kit, EasySampler data is automatically transferred to, and ... experiment, on a touchscreen platform. , EasySampler fully automates the sampling process ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... Among First to Carry New Package, ATLANTA, March ... It! fortified juice beverage for kids, announced today the ... to five all natural,fruit-filled beverages. Shaw,s, ShopRite and Pathmark, ... will be among a host of leading,retailers to introduce ...
... reveals that people who wear glasses are not stereotypical ... myth that people who wear glasses are introverted or ... to be agreeable and open, rather than closed and ... Melbournes Centre for Eye Research Australia. , Myopia or ...
... that focus on usability and ... rapid commercialization, ... product design and development company, serving the life,sciences industry, today ... Research & Development. As the company continues to,expand, Dan furthers ...
... savor the ... health benefits of soy, NORTHRIDGE, Calif., ... to fall in love with soy -- Strawberry and Peanut,Chocolate Chip ... ranks of the original all-natural, baked flavors -- Apple,Walnut, Berry, Mango ...
... TAI,AN, China, March 25 /Xinhua-PRNewswire-FirstCall/ -- China ... CRUI) (,China,RuiTai, or ,the Company,), a leading ... the People,s Republic of China (,PRC,), today,announced ... design and execute its investor,relations campaign., ...
... Can Now Sleep Protected and at Ease With ... Asthma & Allergy Friendly(TM) Bedding, ... of innovative and premium home textile products, today,announced that several ... friendly(TM) by the Asthma and Allergy,Foundation of America (AAFA). This ...
Cached Medicine News:Health News:White Hat Brands Takes Dog On It! Fortified Juice Beverage for Kids to New Heights 2Health News:Mythbusted -- people who wear glasses aren't geeks 2Health News:Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development 2Health News:SOYJOY(R) Introduces Two New Ways to Enjoy Soy 2Health News:China RuiTai International Holdings Retains CCG Elite for Investor Relations Services 2Health News:China RuiTai International Holdings Retains CCG Elite for Investor Relations Services 3Health News:London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products 2Health News:London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products 3
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: